BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF) in patients with Sanfilippo syndrome type A (MPS IIIA).

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in February.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

BioVie Inc. today announced the participation of its management team in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Sensus Healthcare, Inc. announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif.

Mithra, a company dedicated to women’s health, provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.

AlzeCure Pharma AB announced that an abstract on preclinical data with its lead drug candidate NeuroRestore ACD856 has been accepted for a poster presentation at AD/PD 2024, which will be held in Lisbon on March 5-9.

Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.

Curium announced that beginning Friday, April 5, 2024, Ioflupane I 123 Injection will be available for Friday patient administration in the US. This additional day of production allows customers to access the product and capitalize on early morning availability on a day not previously available from Curium.

Qorvis announces the appointment of Dr. Colleen Pietras, M.D., to the position of Chief Medical Officer.